Kyowa Kirin International has announced final results from the German MINT study evaluating mogamulizumab in patients with MF and SS. Presented at the EORTC‑CLTG Annual Meeting 2026, the findings represent one of the largest real‑world evaluations of the therapy in Germany and add to evidence supporting its use in routine practice.
MINT was a company‑sponsored, multicentric, non‑interventional real‑world study across 18 centres. It assessed outcomes in a broad patient population, including clinically relevant subgroups such as LCT and fMF, and stratified by disease stage and MAR status.
MF and SS are forms of CTCL, a type of non‑Hodgkin’s lymphoma that manifests on the skin. Symptoms can include persistent rashes, changes in skin colour and plaques or tumours. These visible symptoms can significantly affect patients’ quality of life.
Professor Chalid Assaf, Director of the Department of Dermatology and Venereology, Helios Klinikum Krefeld, said: “For patients living with mycosis fungoides and Sézary syndrome, understanding how treatments perform outside the controlled setting of clinical trials is critically important.
“The final MINT results demonstrate meaningful clinical outcomes across a broad patient population treated in routine practice and highlight the value of collaborative real-world research in helping clinicians make informed treatment decisions.”
The final analysis included 109 patients, with a median follow‑up of 25.2 months. Most had advanced disease at treatment initiation. The study reported a median TTNT of 14.9 months, a best overall response rate of 62.4% and a median progression‑free survival of 20.2 months. Median overall survival was not estimable due to the limited number of deaths observed.
Exploratory analyses showed best overall response rates of 54.5% in patients with LCT and 50.0% in patients with fMF. Additional analyses by disease stage reported best overall response rates of 50% in early‑stage disease and 64.8% in advanced disease. Disease control rate in patients with MAR was 95.7%.
Patients also experienced improvements in quality of life, with median Skindex‑29 scores improving by 38.5% from baseline to Month 12.
Dr Azeem Danish, Medical Affairs Director, DACH, Kyowa Kirin, explained: “MINT provides valuable real-world evidence from Germany on the use of mogamulizumab across the heterogeneous population of patients with mycosis fungoides and Sézary syndrome, including clinically relevant subgroups that are often underrepresented in clinical trials. By evaluating time-to-next-treatment as a clinically meaningful outcome, the study offers practical insights that can support CTCL specialists in making informed, individualised treatment decisions.”
Investigators concluded that mogamulizumab demonstrated a safety profile comparable to the pivotal phase 3 MAVORIC study, with grade 3 or higher treatment‑related adverse events reported in 38.5% of patients. Serious treatment‑related adverse events leading to discontinuation occurred in 22.0% of patients.
